Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884288 | 0.90 | CTSK (0.52) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL18879598 | 0.86 | CTSK (0.57) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL18875926 | 0.85 | CTSK (0.49) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL16572098 | 0.85 | CTSK (0.55) | CTSKCTSSCAPN1SIRT6SIRT1 | |
| SCHEMBL18875929 | 0.85 | CTSK (0.49) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL17880449 | 0.84 | CTSK (0.45) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL18875923 | 0.84 | CTSK (0.58) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL17898638 | 0.84 | CTSK (0.48) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL15683032 | 0.83 | CA1 (0.49) | CTSKCTSSCAPN1CA1CA2 | |
| SCHEMBL16521489 | 0.82 | MEN1 (0.55) | CTSKCTSSCAPN1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | QPCT, PTMS, MAX | CTSK 194/4885CTSS 203/4885CAPN1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.